CR9293A - Utilizacion de rimonabant para la preparacion de medicamentos utiles en la prevencion y el tratamiento de la diabetes de tipo 2 - Google Patents
Utilizacion de rimonabant para la preparacion de medicamentos utiles en la prevencion y el tratamiento de la diabetes de tipo 2Info
- Publication number
- CR9293A CR9293A CR9293A CR9293A CR9293A CR 9293 A CR9293 A CR 9293A CR 9293 A CR9293 A CR 9293A CR 9293 A CR9293 A CR 9293A CR 9293 A CR9293 A CR 9293A
- Authority
- CR
- Costa Rica
- Prior art keywords
- diabetes
- prevention
- preparation
- treatment
- type
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Utilizacion de rimonabant a solas o asociado con otro principio activo, para la preparacion de medicamentos utiles en la prevencion y el tratamiento de la diabetes de tipo 2 o la diabetes no insulino-dependiente y/o de sus complicaciones.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0501861A FR2882261B1 (fr) | 2005-02-21 | 2005-02-21 | Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2 |
FR0504942A FR2882264A1 (fr) | 2005-02-21 | 2005-05-12 | Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2 |
FR0505228A FR2882265B1 (fr) | 2005-02-21 | 2005-05-23 | Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2. |
Publications (1)
Publication Number | Publication Date |
---|---|
CR9293A true CR9293A (es) | 2007-10-01 |
Family
ID=36809538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR9293A CR9293A (es) | 2005-02-21 | 2007-08-07 | Utilizacion de rimonabant para la preparacion de medicamentos utiles en la prevencion y el tratamiento de la diabetes de tipo 2 |
Country Status (10)
Country | Link |
---|---|
JP (1) | JP2008530189A (es) |
BR (1) | BRPI0608183A2 (es) |
CR (1) | CR9293A (es) |
EA (1) | EA011618B1 (es) |
FR (2) | FR2882264A1 (es) |
IL (1) | IL185401A0 (es) |
MA (1) | MA29262B1 (es) |
MX (1) | MX2007009996A (es) |
TN (1) | TNSN07297A1 (es) |
TW (1) | TW200640457A (es) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2789079B3 (fr) * | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
US20040122033A1 (en) * | 2002-12-10 | 2004-06-24 | Nargund Ravi P. | Combination therapy for the treatment of obesity |
-
2005
- 2005-05-12 FR FR0504942A patent/FR2882264A1/fr not_active Withdrawn
- 2005-05-23 FR FR0505228A patent/FR2882265B1/fr not_active Expired - Fee Related
-
2006
- 2006-02-20 JP JP2007555669A patent/JP2008530189A/ja not_active Withdrawn
- 2006-02-20 MX MX2007009996A patent/MX2007009996A/es not_active Application Discontinuation
- 2006-02-20 EA EA200701781A patent/EA011618B1/ru not_active IP Right Cessation
- 2006-02-20 BR BRPI0608183-5A patent/BRPI0608183A2/pt not_active IP Right Cessation
- 2006-02-20 TW TW095105631A patent/TW200640457A/zh unknown
-
2007
- 2007-07-31 TN TNP2007000297A patent/TNSN07297A1/en unknown
- 2007-08-07 CR CR9293A patent/CR9293A/es unknown
- 2007-08-20 IL IL185401A patent/IL185401A0/en unknown
- 2007-08-23 MA MA30158A patent/MA29262B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
FR2882265B1 (fr) | 2009-02-13 |
BRPI0608183A2 (pt) | 2009-11-17 |
TW200640457A (en) | 2006-12-01 |
MA29262B1 (fr) | 2008-02-01 |
IL185401A0 (en) | 2008-08-07 |
EA011618B1 (ru) | 2009-04-28 |
EA200701781A1 (ru) | 2007-12-28 |
FR2882265A1 (fr) | 2006-08-25 |
MX2007009996A (es) | 2007-10-10 |
FR2882264A1 (fr) | 2006-08-25 |
TNSN07297A1 (en) | 2008-12-31 |
JP2008530189A (ja) | 2008-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2007003227A1 (es) | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo en combinacion con uno o mas agentes terapeuticos; y uso para el tratamiento de diabetes mellitus, obesidad e hiperglucemia entre otras. | |
BRPI0815577A2 (pt) | Peptídeo foxm1 e agente medicinal compreendendo o mesmo. | |
ECSP077401A (es) | Medicamentos que contienen compuestos de carbonilo y su uso | |
HK1121074A1 (en) | Treatment of type 2 diabetes with a combination of dpiv inhibitor and metformin or thiazolidinedione | |
BRPI0615150A2 (pt) | agente para a profilaxia ou tratamento de diabete, sensibilizador de insulina, composto, pró-droga, agente farmacêutico, e, uso do composto ou um sal do mesmo ou uma pró-droga do mesmo | |
EA201100621A1 (ru) | Лечение диабета у пациентов, у которых наблюдается недостаточный гликемический контроль несмотря на лечение пероральным или непероральным противодиабетическим лекарственным средством | |
CL2008002871A1 (es) | Compuestos derivados de oxadiazol-bencimidazol; composicion farmaceutica que los contiene y su uso como inhibidores de dgt1 para el tratamiento de la tolerancia deteriorada a la glucosa, diabetes tipo 2 y obesidad. | |
ES2376043T3 (es) | Derivados de indazol para el tratamiento de enfermedades inducidas por hsp90. | |
PA8637301A1 (es) | Derivados de amino-5, 5-difenilimidazolona para la inhibicion de la b-secretasa | |
IL184051A (en) | Acetylated GLP-1 compounds, containing and using pharmaceutical preparations | |
GT200600046A (es) | Terapia de combinacion | |
SV2006002100A (es) | Tratamiento de la hemorragia de disrupcion en regimenes anticonceptivos extendidos ref. p-sv-78.159/msu | |
AR037407A1 (es) | Composiciones farmaceuticas para el tratamiento de la diabetes mellitus de tipo ii | |
CL2008002162A1 (es) | Compuestos derivados de 3-benzoisoxazol-piperidin; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento y/o prevencion de trastornos cognitivos, adiccion a drogas, depresion, ansiedad, entre otras. | |
CL2007002890A1 (es) | Compuestos derivados de 2-piridincarboxamida, activador de glucosinasa; composicion farmaceutica; y uso del compuesto para el tratamiento de diabetes o la obesidad. | |
CL2008000610A1 (es) | Composicion en forma de dosificacion transdermica o transmucosa que comprende una relacion en peso de buprenorfina a naloxona entre 2,1:1 y 8:1, util para el tratamiento del dolor. | |
BRPI0717369A2 (pt) | Composto, medicamento, composição farmacêutica que o contém e uso do composto. | |
CO6640324A2 (es) | Uso de metformina en combinación con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa | |
CL2007002875A1 (es) | Composicion farmaceutica recubierta por una pelicula que comprende capecitabina y al menos un disgregante, util en el tratamiento del cancer para pacientes que tienen dificultad para tragar las formas de dosificacion solidas orales. | |
ATE392889T1 (de) | Orale antimikrobielle pharmazeutische zusammensetzungen | |
CO6321285A2 (es) | Uso de 3,11b-cis- dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria | |
CL2007003643A1 (es) | Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas. | |
CL2017002293A1 (es) | Tratamiento de pacientes con diabetes mellitus de tipo 2 | |
CL2008003024A1 (es) | Compuestos derivados de alquilsulfonilbenzotiazol, moduladores del receptor de grelina; formulacion farmaceutica; y uso para el tratamiento de obesidad o sobrepeso, diabetes, sindrome metabolico, entre otras. | |
AR050696A1 (es) | Composicion farmaceutica en forma de comprimido de residencia gastrica que contiene un principio activo |